Literature DB >> 28137398

Anti-CCP antibodies are not a marker of severity in established rheumatoid arthritis: a magnetic resonance imaging study.

Lílian Santuza Santos Porto1, Wilson Campos Tavares2, Dário Alves da Silva Costa3, Cristina Costa Duarte Lanna4, Adriana Maria Kakehasi4.   

Abstract

INTRODUCTION: The presence of anti-CCP is an important prognostic tool of rheumatoid arthritis (RA). But research is still ongoing on its relationship with disease activity and functional capacity.
OBJECTIVES: To study the relationship between anti-CCP and disease activity, functional capacity and structural damage indexes, by means of conventional radiography (CR) and magnetic resonance imaging (MRI), in cases of established RA.
METHODS: Cross-sectional study with RA patients with 1-10 disease duration. Participants underwent clinical evaluation with anti-CCP. Disease activity was assessed using the Clinical Disease Activity Index (CDAI), and functional capacity through the Health Assessment Questionnaire (HAQ). CR analysis was carried out by the Sharp van der Heijde index (SvdH), and MRI analysis by RAMRIS (Rheumatoid Arthritis Magnetic Resonance Image Scoring).
RESULTS: We evaluated 56 patients, with a median (IqR) age of 55 (47.5-60) years; 50 (89.3%) participants were female and 37 (66.1%) were positive for anti-CCP. Medians (IqR) of CDAI, HAQ, SvdH and RAMRIS were 14.75 (5.42-24.97) 1.06 (0.28-1.75), 2 (0-8) and 15 (7-35), respectively. There was no association between anti-CCP and CDAI, HAQ and SvdH and RAMRIS scores.
CONCLUSION: Our results have not established an association of anti-CCP with the severity of disease. To date, we cannot corroborate anti-CCP as a prognostic tool in patients with established RA.
Copyright © 2015 Elsevier Editora Ltda. All rights reserved.

Entities:  

Keywords:  Anti-CCP; Atividade de doença; Capacidade funcional; Dano estrutural; Disease activity; Functional capacity; Structural damage

Mesh:

Substances:

Year:  2015        PMID: 28137398     DOI: 10.1016/j.rbre.2015.07.018

Source DB:  PubMed          Journal:  Rev Bras Reumatol Engl Ed        ISSN: 2255-5021


  6 in total

1.  A Study on Association Between Protein Carbonyl and Anti-cyclic Citrullinated Peptide Antibody in Rheumatoid Arthritis: Introducing a New Supplementary Biomarker.

Authors:  Sahar Khorasani; Nadia Boroumand; Abdolmomen Ghaeni Pasavei; Maryam Sahebari; Seyed Isaac Hashemy
Journal:  Indian J Clin Biochem       Date:  2019-03-05

2.  Diagnostic and prognostic value of anti-CarP antibodies in a sample of Egyptian rheumatoid arthritis patients.

Authors:  Sahar A Elsayed; Mohamed A Esmail; Randa M Ali; Omar M Mohafez
Journal:  Clin Rheumatol       Date:  2019-06-03       Impact factor: 2.980

3.  Cytokines (IL-15, IL-21, and IFN-γ) in rheumatoid arthritis: association with positivity to autoantibodies (RF, anti-CCP, anti-MCV, and anti-PADI4) and clinical activity.

Authors:  Itzel Viridiana Reyes-Pérez; Pedro Ernesto Sánchez-Hernández; José Francisco Muñoz-Valle; Gloria Esther Martínez-Bonilla; Trinidad García-Iglesias; Verónica González-Díaz; Samuel García-Arellano; Sergio Cerpa-Cruz; Julissa Polanco-Cruz; María Guadalupe Ramírez-Dueñas
Journal:  Clin Rheumatol       Date:  2019-07-17       Impact factor: 2.980

Review 4.  A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus.

Authors:  Thomas Dörner; Edward M Vital; Sarah Ohrndorf; Rieke Alten; Natalia Bello; Ewa Haladyj; Gerd Burmester
Journal:  Rheumatol Ther       Date:  2022-03-31

5.  Relationship Between Smoking and Structural Damage, Autoimmune Antibodies, and Disability in Rheumatoid Arthritis Patients.

Authors:  Filiz Sivas; Fatma Gül Yurdakul; Ayşegül Kiliçarslan; Semra Duran; Bedriye Başkan; Hatice Bodur
Journal:  Arch Rheumatol       Date:  2017-05-25       Impact factor: 1.472

6.  Elevated Expression of the Long Noncoding RNA IFNG-AS1 in the Peripheral Blood from Patients with Rheumatoid Arthritis.

Authors:  Huiyong Peng; Shuting Ren; Yingzhao Liu; Huimin Zhou; Xinyi Tang; Jun Yang; Jie Tian; Ping Xu; Huaxi Xu; Shengjun Wang
Journal:  J Immunol Res       Date:  2020-01-30       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.